Glyphosate A 'Substantial Factor' In Causing Cancer, Jury Says; Trial Continues

SAN FRANCISCO - A jury in a federal bellwether glyphosate cancer trial in California on March 19 found that the chemical, which is the active ingredient in Monsanto Co.'s herbicide Roundup, was "a substantial factor" in causing the plaintiff's non-Hodgkin lymphoma. Phase 2 of the trial, to determine liability and damages, is slated to begin March 20 (In re: Roundup Products Liability Litigation, MDL No. 2741, N.D. Calif.).
Source: LexisNexis® Mealey's™ Emerging Toxic Torts Legal News - Category: Medical Law Source Type: news

Related Links:

Allergan Inc. is facing legal action after a type of breast implants it sold was linked by Health Canada to a higher risk of a rare form of non-Hodgkin's lymphoma.
Source: CBC | Health - Category: Consumer Health News Tags: News/Canada/Calgary Source Type: news
Cadherins switching is a hallmark of neoplasic processes. The E-cadherin (E-cad) subtype is one of the surface molecules regulating cell-to-cell adhesion. After its cleavage by sheddases, a soluble fragment (sE-cad) is released that has been identified as a pro-carcinogenic inflammatory signal in several bacteria-induced cancers. Recently we reported that Q fever, a disease due to Coxiella burnetii infection, can be complicated by occurrence of non-Hodgkin lymphoma (NHL). Therefore, we studied E-cad switching in Q fever. The sE-cad levels were found increased in the sera of acute and persistent Q fever patients, whereas th...
Source: Frontiers in cellular and infection microbiology - Category: Microbiology Source Type: research
AbstractPurpose of ReviewMantle cell lymphoma is a CD5+ non-Hodgkin lymphoma associated with suboptimal outcome. Young, fit patients are generally offered intensive induction followed by autologous hematopoietic cell transplantation (AHCT) in first remission. Some patients may not benefit from this strategy.Recent FindingsRecent studies have investigated the role of AHCT in the modern era. First, an analysis of the National Cancer Database demonstrated improved progression-free survival (PFS) for consolidative AHCT. Second, a multi-center study associated consolidative AHCT with improved PFS even after propensity-weighted ...
Source: Current Hematologic Malignancy Reports - Category: Hematology Source Type: research
Lymphomas are the heterogeneous group of malignant diseases characterized by proliferation of malignant lymphoid cells or their precursors. Lymphomas are the ninth most common cancer worldwide and constitute 3.2% of malignant tumor. Lymphomas are generally classified to two main categories: Hodgkin's lymphomas (HL) and the non-Hodgkin lymphomas (NHL), and about 90% are NHL. Non-Hodgkin lymphoma represents 4.3% of all new cancer cases in the U.S. and the ninth most common cancer in male patient of Taiwan.
Source: Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics - Category: ENT & OMF Authors: Tags: #25 Source Type: research
Danny Feltwell Jr, 10, suffered from non-Hodgkin lymphoma. A bone marrow transplant treated his relapse, but then he got graft-versus-host disease. An experimental treatment has him back to pitching.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news
A gardener in Australia has sued Bayer over its Monsanto Roundup weedkiller, the first such lawsuit against the German pharmaceutical giant in that country. Michael Ogalirolo, 54, a self-employed gardener from Melbourne, said he was diagnosed with non-Hodgkin lymphoma, a type of leukemia, after using Monsanto’s Roundup for more than 20 years, Reuters reported. “We have great sympathy for any individual with cancer, but the extensive body of scie nce on glyphosate-based herbicides over four…
Source: Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news
Varrie Dunlop, 26, of Ringwood, Hampshire, was diagnosed with stage four non-Hodgkin's lymphoma last November after doctors initially dismissed her fatigue as a viral infection.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news
Targeting IL-6 receptor reduces IgM levels and tumor growth in Waldenström macroglobulinemia. Oncotarget. 2019 May 21;10(36):3400-3407 Authors: Han W, Matissek SJ, Jackson DA, Sklavanitis B, Elsawa SF Abstract The tumor microenvironment (TME) plays an important role in cancer cell biology and is implicated in resistance to therapy. In Waldenström macroglobulinemia (WM), a subtype of Non-Hodgkin lymphoma, the TME modulates WM biology by secreting cytokines that promote the malignant phenotype. In previous work, we have shown that TME-IL-6 promotes WM cell growth and IgM secretion in WM. Tocili...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
Conclusion: We report for the first time a case of a patient with Muir-Torre syndrome who developed an orbital recurrent SC with an incidental finding of a lacrimal gland B non-Hodgkin lymphoma consistent with SLL. Clinicians should be aware of the possibility of this coexistence of multiple cancer types in patients with sebaceous carcinoma and Muir-Torre syndrome.Ocul Oncol Pathol
Source: Ocular Oncology and Pathology - Category: Opthalmology Source Type: research
PHILADELPHIA - A husband and wife on May 30 sued Monsanto Co. in federal court in Pennsylvania, contending that the wife developed non-Hodgkin lymphoma (NHL) as a result of exposure to the company's herbicide Roundup, which the plaintiffs say was marketed despite the company's knowledge that it causes cancer (Ruth Yobs, et al. v. Monsanto Co., No. 19-2362, E.D. Pa.).
Source: LexisNexis® Mealey's™ Emerging Toxic Torts Legal News - Category: Medical Law Source Type: news
More News: Cancer | Cancer & Oncology | Chemistry | Legislation | Lymphoma | Medical Law | Non-Hodgkin's Lymphoma | Toxicology